The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly ...

Edwards Lifesciences (NYSE: EW) today announced eight-year data highlighting positive long-term outcomes with its proprietary ...

Edwards Lifesciences (EW) announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary ...

The Heart Valve Devices Market is valued at USD 12.18 Billion in 2024 and is expected to reach USD 41.88 Billion by 2035 at a ...

Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

The two companies have entered into a strategic partnership to exclusively commercialize Braile’s Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other ...